Predicting response and survival in chemotherapy-treated triple-negative breast cancer
Aleix Prat(Breast Cancer Research Foundation), Emilio Alba(Hospital Clínico Universitario Virgen de la Victoria), Miguel Ángel Seguí, Maggie C.U. Cheang(Institute of Cancer Research), Brandelyn N. Pitcher(Statistical and Applied Mathematical Sciences Institute), Aňa Lluch(Hospital Clínico Universitario de Valencia), Joan Albanell(Universitat Pompeu Fabra), Lourdes Calvo(Complexo Hospitalario Universitario A Coruña), Tammi L. Vickery(Washington University in St. Louis), Eva Carrasco(Heidelberg University), Manuel Ruíz‐Borrego(Hospital Universitario Virgen del Rocío), Marc L. Citron(Northwell Health), Clifford A. Hudis(American Society of Clinical Oncology), Lisa A. Carey(UNC Lineberger Comprehensive Cancer Center), Elaine R. Mardis(Nationwide Children's Hospital), Joel S. Parker(University of North Carolina at Chapel Hill), Matthew J. Ellis(Baylor College of Medicine), Ángel Guerrero(Fundación Instituto Valenciano de Oncología), Charles M. Perou(Segeberger Kliniken), José Ignacio Chacón(Hospital Virgen de la Salud), Eric P. Winer(University of Vermont), M C Liu(Mayo Clinic in Arizona), Álvaro Rodríguez-Lescure(Hospital General Universitario de Elche), Rosalía Caballero(GEICAM – Spanish Breast Cancer Group), Margaret L. Gulley(University of North Carolina at Chapel Hill), Àngels Arcusa(Consorci Sanitari de Terrassa), Arrate Plazaola(Onkologikoa), Nuria Ribelles(Instituto de Investigación Biomédica de Málaga), Octavio Burgués(Hospital Clínico Universitario de Valencia), Yingying Li(Capital Medical University), Zhiyuan Hu(University of North Carolina at Chapel Hill), Miguel Martín(Hospital General Universitario Gregorio Marañón), José Antonio López(Hospital Clínico San Carlos), Cheng Fan(University of North Carolina at Chapel Hill), B. Munárriz(Hospital Universitari i Politècnic La Fe), María Vidal(Inserm), William T. Barry(Harvard University), Bárbara Adamo(Hospital Clínic de Barcelona)
Cited by 113
Related Papers
A global reference for human genetic variation
|Nature|2015|19.9k
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
|Clinical Cancer Research|2004|2.7k